Swedish Orphan Biovitrum (BIOVF)
(Delayed Data from OTC)
$31.28 USD
0.00 (0.00%)
Updated Aug 30, 2024 11:57 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Swedish Orphan Biovitrum falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 85 | 135 | 122 | 44 | 78 |
Receivables | 544 | 575 | 441 | 460 | 451 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 365 | 330 | 399 | 333 | 187 |
Other Current Assets | 200 | 70 | 61 | 53 | 58 |
Total Current Assets | 1,195 | 1,111 | 1,024 | 890 | 775 |
Net Property & Equipment | 24 | 27 | 57 | 58 | 55 |
Investments & Advances | 13 | 12 | 23 | 20 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 80 | 87 | 89 | 67 | 37 |
Intangibles | 5,669 | 3,965 | 4,480 | 4,228 | 3,958 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6,981 | 5,202 | 5,674 | 5,263 | 4,831 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 97 | 124 | 65 | 62 | 72 |
Current Portion Long-Term Debt | 831 | 574 | 206 | 438 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 495 | 521 | 579 | 428 | 322 |
Income Taxes Payable | 7 | 2 | 5 | 56 | 30 |
Other Current Liabilities | 357 | 238 | 153 | 142 | 174 |
Total Current Liabilities | 1,801 | 1,472 | 1,022 | 1,138 | 607 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 630 | 376 | 420 | 378 | 394 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,071 | 294 | 1,023 | 1,105 | 1,708 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 270 | 411 | 474 | 406 | 296 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3,787 | 2,574 | 2,968 | 3,060 | 3,039 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 18 | 17 | 20 | 18 | 17 |
Capital Surplus | 1,561 | 1,012 | 1,160 | 1,070 | 1,026 |
Retained Earnings | 1,703 | 1,565 | 1,534 | 1,142 | 769 |
Other Equity | -88 | 35 | -8 | -28 | -21 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3,194 | 2,629 | 2,705 | 2,202 | 1,791 |
Total Liabilities & Shareholder's Equity | 6,981 | 5,202 | 5,674 | 5,263 | 4,831 |
Total Common Equity | 3,194 | 2,629 | 2,705 | 2,202 | 1,791 |
Shares Outstanding | 295.10 | 295.10 | 295.10 | 299.90 | NA |
Book Value Per Share | 10.82 | 8.91 | 9.17 | 7.34 | -0.02 |
Fiscal Year End for Swedish Orphan Biovitrum falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 51 | 85 | 63 | 75 |
Receivables | NA | 770 | 544 | 594 | 566 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 343 | 365 | 363 | 387 |
Other Current Assets | NA | 0 | 200 | 0 | 0 |
Total Current Assets | NA | 1,163 | 1,195 | 1,020 | 1,028 |
Net Property & Equipment | NA | 25 | 24 | 24 | 29 |
Investments & Advances | NA | 19 | 13 | 15 | 12 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 79 | 80 | 75 | 81 |
Intangibles | NA | 5,875 | 5,669 | 5,857 | 6,049 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 7,161 | 6,981 | 6,990 | 7,199 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 64 | 97 | 98 | 89 |
Current Portion Long-Term Debt | NA | 721 | 831 | 301 | 1,001 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 495 | 0 | 0 |
Income Taxes Payable | NA | 0 | 7 | 0 | 0 |
Other Current Liabilities | NA | 845 | 357 | 854 | 642 |
Total Current Liabilities | NA | 1,644 | 1,801 | 1,265 | 1,747 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 662 | 630 | 691 | 715 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1,096 | 1,071 | 1,619 | 1,642 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 270 | 214 | 380 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3,711 | 3,787 | 3,805 | 4,504 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 19 | 18 | 18 | 16 |
Capital Surplus | NA | 1,594 | 1,561 | 1,489 | 958 |
Retained Earnings | NA | 1,810 | 1,703 | 1,604 | 1,639 |
Other Equity | NA | 27 | -88 | 74 | 82 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 3,450 | 3,194 | 3,185 | 2,696 |
Total Liabilities & Shareholder's Equity | NA | 7,161 | 6,981 | 6,990 | 7,199 |
Total Common Equity | 0 | 3,450 | 3,194 | 3,185 | 2,696 |
Shares Outstanding | NA | NA | 295.10 | 295.10 | 295.10 |
Book Value Per Share | 0.00 | -0.03 | 10.82 | 10.79 | 9.13 |